Skip to content
  • Home Home Home, current page.
  • Moments Moments Moments, current page.

Saved searches

  • Remove
  • In this conversation
    Verified accountProtected Tweets @
Suggested users
  • Verified accountProtected Tweets @
  • Verified accountProtected Tweets @
  • Language: English
    • Bahasa Indonesia
    • Bahasa Melayu
    • Català
    • Čeština
    • Dansk
    • Deutsch
    • English UK
    • Español
    • Filipino
    • Français
    • Hrvatski
    • Italiano
    • Magyar
    • Nederlands
    • Norsk
    • Polski
    • Português
    • Română
    • Slovenčina
    • Suomi
    • Svenska
    • Tiếng Việt
    • Türkçe
    • Ελληνικά
    • Български език
    • Русский
    • Српски
    • Українська мова
    • עִבְרִית
    • العربية
    • فارسی
    • मराठी
    • हिन्दी
    • বাংলা
    • ગુજરાતી
    • தமிழ்
    • ಕನ್ನಡ
    • ภาษาไทย
    • 한국어
    • 日本語
    • 简体中文
    • 繁體中文
  • Have an account? Log in
    Have an account?
    · Forgot password?

    New to Twitter?
    Sign up
zeynep's profile
zeynep tufekci
zeynep tufekci
zeynep tufekci
Verified account
@zeynep

Tweets

zeynep tufekciVerified account

@zeynep

Complex systems, wicked problems. Society, technology, science and more. @UNC professor. @NYTimes columnist. My newsletter is @insight: http://www.theinsight.org 

floating in a most peculiar way
theinsight.org
Joined August 2009

Tweets

  • © 2022 Twitter
  • About
  • Help Center
  • Terms
  • Privacy policy
  • Cookies
  • Ads info
Dismiss
Previous
Next

Go to a person's profile

Saved searches

  • Remove
  • In this conversation
    Verified accountProtected Tweets @
Suggested users
  • Verified accountProtected Tweets @
  • Verified accountProtected Tweets @

Promote this Tweet

Block

  • Tweet with a location

    You can add location information to your Tweets, such as your city or precise location, from the web and via third-party applications. You always have the option to delete your Tweet location history. Learn more

    Your lists

    Create a new list


    Under 100 characters, optional

    Privacy

    Copy link to Tweet

    Embed this Tweet

    Embed this Video

    Add this Tweet to your website by copying the code below. Learn more

    Add this video to your website by copying the code below. Learn more

    Hmm, there was a problem reaching the server.

    By embedding Twitter content in your website or app, you are agreeing to the Twitter Developer Agreement and Developer Policy.

    Preview

    Why you're seeing this ad

    Log in to Twitter

    · Forgot password?
    Don't have an account? Sign up »

    Sign up for Twitter

    Not on Twitter? Sign up, tune into the things you care about, and get updates as they happen.

    Sign up
    Have an account? Log in »

    Two-way (sending and receiving) short codes:

    Country Code For customers of
    United States 40404 (any)
    Canada 21212 (any)
    United Kingdom 86444 Vodafone, Orange, 3, O2
    Brazil 40404 Nextel, TIM
    Haiti 40404 Digicel, Voila
    Ireland 51210 Vodafone, O2
    India 53000 Bharti Airtel, Videocon, Reliance
    Indonesia 89887 AXIS, 3, Telkomsel, Indosat, XL Axiata
    Italy 4880804 Wind
    3424486444 Vodafone
    » See SMS short codes for other countries

    Confirmation

     

    Welcome home!

    This timeline is where you’ll spend most of your time, getting instant updates about what matters to you.

    Tweets not working for you?

    Hover over the profile pic and click the Following button to unfollow any account.

    Say a lot with a little

    When you see a Tweet you love, tap the heart — it lets the person who wrote it know you shared the love.

    Spread the word

    The fastest way to share someone else’s Tweet with your followers is with a Retweet. Tap the icon to send it instantly.

    Join the conversation

    Add your thoughts about any Tweet with a Reply. Find a topic you’re passionate about, and jump right in.

    Learn the latest

    Get instant insight into what people are talking about now.

    Get more of what you love

    Follow more accounts to get instant updates about topics you care about.

    Find what's happening

    See the latest conversations about any topic instantly.

    Never miss a Moment

    Catch up instantly on the best stories happening as they unfold.

    1. Rajeev Venkayya MD‏Verified account @rvenkayya 11 Dec 2020
      Replying to @rvenkayya @JonLoflin and

      That said, there are good reasons to believe a one-dose schedule may not be as efficacious as a two-dose schedule, including against severe disease in high-risk populations, due to magnitude, duration and quality of the immune response. 3/

      1 reply 1 retweet 5 likes
    2. Rajeev Venkayya MD‏Verified account @rvenkayya 11 Dec 2020
      Replying to @rvenkayya @JonLoflin and

      No one here is saying one dose is as good as two, but some may interpret early efficacy to mean one dose is sufficient, for all vaccines, before we have any data. We need to be clear about what we do and don’t know and prepare people for revised guidance as we learn more. 4/

      1 reply 1 retweet 4 likes
    3. zeynep tufekci‏Verified account @zeynep 11 Dec 2020
      Replying to @rvenkayya @JonLoflin and

      I'd say the way to figure out the "some may" risk is to communicate clearly, not avoid the trade-off discussion. One twist for this is the age risk is well-defined and exponential so we can make sure to communicate that. (In fact, more boosters for 65+? Anyone looking at that?)

      1 reply 0 retweets 4 likes
    4. zeynep tufekci‏Verified account @zeynep 11 Dec 2020
      Replying to @zeynep @rvenkayya and

      I get durability risk without booster(s?) but severe disease is not equally distributed, and dampening the outbreak rapidly is worth a lot (both the disease risk and the downsides to the world of this situation). If we don't put this on agenda now, it won't even be considered.

      1 reply 0 retweets 4 likes
    5. zeynep tufekci‏Verified account @zeynep 11 Dec 2020
      Replying to @zeynep @rvenkayya and

      What Michael and I are urging is to have the mindset, now, to start whatever we can to put this on a sound(er) footing—something we should have started earlier. Start recruiting Monday for a volunteer placebo arm for the second dose among lower-risk HCW to be vaccinated, for ex.

      1 reply 0 retweets 4 likes
    6. Rajeev Venkayya MD‏Verified account @rvenkayya 11 Dec 2020
      Replying to @zeynep @JonLoflin and

      That's a new efficacy study, which can certainly be done but not overnight. We'll have more data to inform this discussion soon. The immunogenicity data will allow us to compare kinetics of response and potential correlates of protection in single- vs two-dose recipients.

      1 reply 0 retweets 2 likes
    7. zeynep tufekci‏Verified account @zeynep 11 Dec 2020
      Replying to @rvenkayya @JonLoflin and

      Yeah it should be a discussion and rapid action before two-dose ossifies simply due to inertia rather than data against. We got a vaccine in basically nine months (amazing!!) but the lack of urgency in conducting more and many trials on everything is very frustrating.

      0 replies 0 retweets 6 likes
    8. This Tweet is unavailable.
    9. zeynep tufekci‏Verified account @zeynep 11 Dec 2020
      Replying to @K_G_Andersen @rvenkayya and

      Single dose trial won't be launched unless there's pressure—there is already inertia, before even trying! (I've seen science journalists already confusing statistical lack of power with lack of efficacy). Lack of urgency=I think we should have started in Nov. given prelim data.+

      3 replies 0 retweets 5 likes
    10. zeynep tufekci‏Verified account @zeynep 11 Dec 2020
      Replying to @zeynep @K_G_Andersen and

      Also think of what UK/NHS did (and give us dexa!) and what we did not do here—randomize and do clinical trials even when we didn't know what was what. We could have done cluster studies for masks/hepa filters/ventilation etc. too.

      1 reply 0 retweets 4 likes
      zeynep tufekci‏Verified account @zeynep 11 Dec 2020
      Replying to @zeynep @K_G_Andersen and

      Also immunologists raise durability & high-risk groups—I get it, very real concerns—but a lot of the broader conversation is already mired in that 52.4% efficacy figure and the statistical illiteracy already surrounding it. I'm hoping we move to conversation to the real issues!

      2:44 PM - 11 Dec 2020
      • 3 Likes
      • Jon L Filialleiter Rajeev Venkayya MD
      1 reply 0 retweets 3 likes
        1. zeynep tufekci‏Verified account @zeynep 11 Dec 2020
          Replying to @zeynep @K_G_Andersen and

          In sum, push for trial now, maybe we get one hopefully quick. Raise the topic now, maybe we can fight unsupported ossification of practice... Just getting to that point would be excellent I think, rather than inertia!

          0 replies 0 retweets 0 likes
          Thanks. Twitter will use this to make your timeline better. Undo
          Undo
        1. This Tweet is unavailable.
        2. zeynep tufekci‏Verified account @zeynep 11 Dec 2020
          Replying to @K_G_Andersen @rvenkayya and

          Yeah. But every side of this is peril. I'm also worried about losing the placebo arm after the EUA, and that we're not doing some regular/random swabs in the trials. Also why a unified protocol? The age risk gradation is steep for 65+ (maybe another booster? Anyone checking?)

          1 reply 0 retweets 4 likes
        3. Show replies

      Loading seems to be taking a while.

      Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.

        Promoted Tweet

        false

        • © 2022 Twitter
        • About
        • Help Center
        • Terms
        • Privacy policy
        • Cookies
        • Ads info